MTOR and neoplasm: For example, we predicted that five drugs (bleomycin, daporinad, sepantronium bromide, etoposide, and ICL1100013) are more specific for basal-like breast cancer subtypes whereas ABT737 and navitoclax sapitinib and afatinib are more specific for the luminal subtypes especially luminal B. We predicted that OSI-027 (mTOR inhibitor) is specific for breast cancer among all 33 TCGA tumor types, especially the Her2-positive breast cancer subtype.